Ovarian Cancer

What researchers are actively studying

Several Phase 3 trials are addressing important questions in ovarian cancer management. One is comparing one versus two years of olaparib with or without bevacizumab as maintenance therapy after frontline treatment, examining whether longer PARP inhibitorDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation → duration extends benefit. Another Phase 3 study is evaluating sacituzumab tirumotecan, a TROP2-targeting ADC, in patients with non-HRD positive advanced ovarian cancer. A Phase 3 trial is testing pembrolizumab combined with paclitaxel with or without bevacizumab for platinum-resistant recurrent disease.

Novel cell therapies are being explored. A Phase 1 trial is evaluating dual-targeting CAR-NK (chimeric antigen receptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → natural killer) cells against mesothelin, FR-alpha, and MUC16. A Phase 2 trial is studying gemcitabine with or without the WEE1 inhibitor adavosertib in recurrent disease, targeting a DNA damage response pathway.

Research from recent literature identifies NRF2 (nuclear factor erythroid 2-related factor 2) as a driver of chemoresistance in ovarian cancer stem-like cells and describes platelet-induced VISTA expression as a mechanism of immune modulation in the tumor microenvironment, providing potential new targets.

Early detection research is active, with studies examining new biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → panels and imaging approaches for earlier diagnosis.

Where the evidence stands

Frontline platinum/taxane chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and PARP inhibitorDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation → maintenance have strong Phase 3 evidence. PARP inhibitorsDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation → are particularly well-supported for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →-mutated and HRD-positive tumors. Mirvetuximab soravtansine has Phase 3 backing for platinum-resistant FR-alpha-positive disease. Treatment after multiple prior lines of therapy remains challenging. Phase 3 trials in recurrent disease are examining newer ADCs and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations. CAR-NK cells, alpha-emitter radionuclide therapies, and novel checkpoint combinations are at Phase 1.

What this means for people affected

Ovarian cancer treatment has benefited significantly from PARP inhibitorsDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation → for patients with BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → or HRD, and molecular testing is now standard in guiding maintenance choices. Platinum-resistant disease remains a difficult clinical category, though mirvetuximab soravtansine offers a newer targeted option in FR-alpha-positive tumors. Research is examining whether extending PARP inhibitorDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation → duration, combining with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →, or using novel cell therapies can further improve outcomes across a broader group of patients.